CLINICAL TRIALS PROFILE FOR SANCUSO
✉ Email this page to a colleague
All Clinical Trials for SANCUSO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00186628 ↗ | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | Completed | National Cancer Institute (NCI) | Phase 2 | 2005-06-01 | To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD) |
| NCT00186628 ↗ | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | Completed | The Leukemia and Lymphoma Society | Phase 2 | 2005-06-01 | To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD) |
| NCT00186628 ↗ | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | Completed | Stanford University | Phase 2 | 2005-06-01 | To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD) |
| NCT00450801 ↗ | R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma | Completed | University of Miami | Phase 2 | 2004-04-01 | RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy followed by thalidomide works in treating patients with previously untreated mantle cell lymphoma. |
| NCT00868764 ↗ | An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron | Completed | Prostrakan Pharmaceuticals | Phase 1 | 2009-04-01 | This study aims to evaluate the effect of age and BMI on the pharmacokinetics and safety of Sancuso®. |
| NCT00873197 ↗ | PK, Tolerability and Safety of the co-Administration of Sancuso® (Transdermal Granisetron) and IV Granisetron | Completed | Prostrakan Pharmaceuticals | Phase 1 | 2009-04-01 | This study has been designed to investigate the pharmacokinetic and safety profile of the co-administration of intravenous (IV) and transdermal granisetron, as well as characterise the pharmacokinetics of multiple transdermal dosing. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SANCUSO
Condition Name
| Condition Name for SANCUSO | |
| Intervention | Trials |
| Chemotherapy Induced Nausea and Vomiting | 3 |
| Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV) | 2 |
| Chemotherapy-induced Nausea and Vomiting (CINV) | 2 |
| Healthy | 2 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for SANCUSO
Trials by Country
Clinical Trial Progress for SANCUSO
Clinical Trial Phase
Clinical Trial Sponsors for SANCUSO
Sponsor Name
